Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
|
Add to portfolio |
|
|
|
| Price: |
$115.57
| | Metrics |
| OS: |
18.5
|
M
| |
|
|
| Market cap: |
$2.13
|
B
| |
|
|
|
Net cash:
|
$99.9
|
M
| |
$5.41
|
per share
|
|
EV:
|
$2.03
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Research and development | 245.4 | 205.2 | 184.8 | 72.3 | 25.4 | 24.4 | 15.9 | 2.4 |
| General and administrative | 48.1 | 37.3 | 21.9 | 22.6 | 15.3 | 7.7 | 9.3 | 0.8 |
| EBIT | -293.6 | -242.5 | -206.7 | -95.0 | -40.7 | -32.1 | -25.2 | -3.2 |
| EBIT margin | | | | | | | | |
| Pre-tax income | -295.4 | -241.8 | -202.2 | -83.9 | -32.8 | -31.2 | -26.4 | -6.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -295.4 | -241.8 | -202.2 | -83.9 | -32.8 | -31.2 | -26.4 | -6.8 |
| Net margin | | | | | | | | |
| |
| Diluted EPS | ($17.24) | ($14.63) | ($13.09) | ($5.45) | ($2.22) | ($2.54) | ($5.07) | ($40.03) |
| Shares outstanding (diluted) | 17.1 | 16.5 | 15.4 | 15.4 | 14.8 | 12.2 | 5.2 | 0.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|